List view / Grid view
20 October 2025 | By
The balance between speed, scale, and compliance has never been more critical. As GLP-1s, biosimilars, and advanced therapies reshape global priorities, pharma leaders face a new question: how can manufacturing infrastructure evolve fast enough to keep pace?
Polyelectrolyte multilayers (PEMs) are promising drug carriers with potential applications in the delivery of poorly soluble drugs. In this article, Sumayah Abdul-Jabbar and Paul Royall discuss the approaches for PEM construction and drug release and detail several applications of multilayered particles in therapeutics.
Extractables and Leachables Safety Information Exchange (ELSIE) has been the most influential industry group in developing guidelines for extractables and leachables. In the wake of the ICH convening a new group to develop a concept paper and business plan on their Q3E Impurity Guideline, Dave Elder discusses the strides that…
The recombinant Factor C (rFC) assay has been developed to help alleviate the pressures of a growing demand for the Limulus amoebocyte lysate (LAL) assay. Here, Sven Deutschmann and Johannes Reich discuss the advantages of rFC and its recent recognition by the European Pharmacopoeia as an alternative endotoxin test.
Any envisioning of ‘the future’ of testing contains elements extrapolated from the past.
In this guide to Analytical Testing, SUEZ explains how to maximise efficiency without compromising on quality.
European Pharmaceutical Review explores how plants can be used for large-scale, glycosylated protein bioproduction for the pharma industry.
Dr Finn Bauer discusses how Merck KGaA and its SAFC® portfolio brand is addressing drug formulator challenges.
In the light of recent media coverage about product recalls – particularly resulting from the detection and presence of NDMA – this article outlines ways to avoid the wide-ranging negative impacts on patients, pharmacies, manufacturers, pharmaceutical companies and health authorities and offers ways to mitigate the risk of future recalls.
Within this in-depth focus are articles on how the regulation of heavy metals in cannabis can benefit from lessons learned in pharma and the advantages of using electron paramagnetic resonance (EPR) as an imaging technique.
In this in-depth focus are articles discussing how to optimise production by using the correct tablet tooling and why logistics can be affected by developments in the pharmaceutical industry.
Included in this in-depth focus is an analysis of the benefits of using polyelectrolyte multilayers as therapeutic agent carriers and a comparison of various methods to characterise the flowability of powder blends.
Within this issue are articles which investigate polyelectrolyte multilayers as drug carriers, discuss how developments in pharma impact logistics and examine how the industry can regulate heavy metals in medicinal cannabis. Other features include how to use the correct tablet tooling and trends for the CDMO sector this year.
Bart Vansteenkiste explains why it is important to validate pharmaceutical labelling compliance to ensure good manufacturing practice.
Researchers at Aston University and Birmingham Children’s Hospital, UK, have discovered a highly effective three-drug approach to treat Mycobacterium abscessus (M. abscessus), a notoriously drug-resistant pathogen that affects up to 13 percent of cystic fibrosis (CF) patients in the UK.
Drug shortages can greatly impact patients and the pharmaceutical industry. Adrian van den Hoven, Director General of Medicines for Europe, explains how to prevent and reduce the effects of medicinal scarcities in the EU.
